AUROPHARMA

AUROBINDO PHARMA

Large Cap BSE: 524804 NSE: AUROPHARMA
₹509.7
9.15 (1.83%)
As on 30 September, 2022 | 02:29

Aurobindo Pharma Share Price

Aurobindo Pharma Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in AUROBINDO PHARMA

Start SIP

Aurobindo Pharma Share Returns

  • Over 1 Month -5.56%
  • Over 3 Month -0.92%
  • Over 6 Month -26.44%
  • Over 1 Year -29.98%

Aurobindo Pharma Key Statistics

P/E Ratio 12.4
PEG Ratio -0.2
Market Cap Cr 29,865
Price to Book Ratio 1.2
EPS 26.2
Dividend 1.5
Relative Strength Index 37.72
Money Flow Index 31.3
MACD Signal -9.27
Average True Range 13.41

Aurobindo Pharma Investment Rating

  • Master Rating:
  • Aurobindo Pharma has an operating revenue of Rs. 23,989.43 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 15% is great, ROE of 10% is good. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 48 which is a POOR score indicating inconsistency in earnings, a RS Rating of 12 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 124 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Aurobindo Pharma Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 2,7352,8782,6142,8722,8864,104
Operating Expenses Qtr Cr 2,5452,3802,4072,5432,4663,138
Operating Profit Qtr Cr 242507216340428976
Depreciation Qtr Cr 10310110198115124
Interest Qtr Cr 854356
Tax Qtr Cr 48-633123120241
Net Profit Qtr Cr 122802240198215873

Aurobindo Pharma Technicals

EMA & SMA

Current Price
509.7
9.15 (1.83%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 526.96
  • 50 Day
  • 540.69
  • 100 Day
  • 558.84
  • 200 Day
  • 606.46
  • 20 Day
  • 530.45
  • 50 Day
  • 547.68
  • 100 Day
  • 542.26
  • 200 Day
  • 606.46

Aurobindo Pharma Resistance and Support

PIVOT
₹501.2
Resistance
First Resistance 504.45
Second Resistance 508.35
Third Resistance 511.6
RSI 37.72
MFI 31.3
MACD Single Line -9.27
MACD -12.33
Support
First Resistance 497.3
Second Resistance 494.05
Third Resistance 490.15

Aurobindo Pharma Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 2,347,119 139,207,628 59.31
Week 1,467,078 66,326,605 45.21
1 Month 1,285,538 54,661,076 42.52
6 Month 1,772,801 56,073,697 31.63

Aurobindo Pharma Result Highlights

Aurobindo Pharma Synopsis

NSE-Medical-Generic Drugs

Aurobindo Pharma is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 11287.14 Cr. and Equity Capital is Rs. 58.59 Cr. for the Year ended 31/03/2022. Aurobindo Pharma Ltd. is a Public Limited Listed company incorporated on 26/12/1986 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1986PLC015190 and registration number is 015190.
Market Cap 29,865
Sales 11,180
Shares in Float 28.12
No of funds 622
Yield 1.77
Book Value 1.74
U/D Vol ratio 0.9
LTDebt / Equity
Alpha -0.12
Beta 0.96

Aurobindo Pharma

Owner NameJun-22Mar-22Dec-21Sep-21
Promoters 51.83%51.83%51.83%
Mutual Funds 9.82%10.09%9.56%
Insurance Companies 5.76%5.73%5.55%
Foreign Portfolio Investors 20.71%20.83%21.37%
Financial Institutions/ Banks
Individual Investors 8.8%8.37%8.98%
Others 3.08%3.15%2.71%

Aurobindo Pharma Management

Name Designation
Mr. K Ragunathan Non Executive Chairman
Mr. K Nithyananda Reddy Vice Chairman & Mng.Director
Mr. P Sarath Chandra Reddy Whole Time Director
Dr. M Sivakumaran Whole Time Director
Mr. M Madan Mohan Reddy Whole Time Director
Mr. P V Ramprasad Reddy Non Executive Director
Mrs. Savita Mahajan Ind. Non-Executive Director
Mr. Girish P Vanvari Ind. Non-Executive Director
Dr.(Mrs.) Avnit Bimal Singh Ind. Non-Executive Director

Aurobindo Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Aurobindo Pharma Corporate Action

Date Purpose Remarks
2022-08-11 Quarterly Results
2022-05-30 Audited Results & 4th Interim Dividend
2022-02-09 Quarterly Results & 3rd Interim Dividend
2021-11-08 Quarterly Results & 2nd Interim Dividend
2021-08-12 Quarterly Results & Interim Dividend
Date Purpose Remarks
2022-06-07 INTERIM Rs.4.50 per share (450%) Fourth Interim Dividend
2022-02-21 INTERIM Rs.1.50 per share(150%)Third Interim Dividend
2021-11-18 INTERIM Rs.1.50 per share (150%) Second Interim Dividend
2021-08-30 INTERIM Rs.1.50 per share(150%)Interim Dividend
2021-02-23 INTERIM Rs.1.50 per share (150%) Third Interim Dividend

Aurobindo Pharma MF Shareholding

Name Amount(cr)
HDFC Balanced Advantage Fund Growth 48055
HDFC Mid-Cap Opportunities Fund Growth 34227
SBI Bluechip Fund Regular Growth 34043
HDFC Flexi Cap Fund Growth 30473
Mirae Asset Emerging Bluechip Fund Growth 23510

Aurobindo Pharma FAQs

What is Share Price of Aurobindo Pharma ?

Aurobindo Pharma share price is ₹509 As on 30 September, 2022 | 02:15

What is the Market Cap of Aurobindo Pharma ?

The Market Cap of Aurobindo Pharma is ₹29865.3 Cr As on 30 September, 2022 | 02:15

What is the P/E ratio of Aurobindo Pharma ?

The P/E ratio of Aurobindo Pharma is 12.4 As on 30 September, 2022 | 02:15

What is the PB ratio of Aurobindo Pharma ?

The PB ratio of Aurobindo Pharma is 1.2 As on 30 September, 2022 | 02:15

Is it a good time to invest in Aurobindo Pharma?

Aurobindo Pharma has an operating revenue of Rs.24,010.31 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 30% is great. Many brokers and analysts have recommended 'Buy' on the stock.

How many times have Aurobindo Pharma given dividends since 2000?

Aurobindo Pharma Ltd. has declared 40 dividends since May 10, 2000.

What is the stock price CAGR of Aurobindo Pharma?

The stock price CAGR of Aurobindo Pharma for 10 Years is 30%, 5 Years is 0%, 3 Years is -3%, 1 Year is -25%.

What is the ROE of Aurobindo Pharma?

Aurobindo Pharma has an ROE of 24% which is exceptional.

What is Aurobindo Pharma’s debt to equity?

Aurobindo Pharma has a reasonable debt to equity of 1%, which signals a healthy balance sheet.

Q1FY23